US FDA Cell/Gene Therapy Office ‘Aggressively Recruiting’ Amid Reorg, Senior Staff Departures
Executive Summary
Transformation of former Office of Tissues and Advanced Therapies into a ‘super office’ will provide leadership opportunities for a younger generation, retiring director Wilson Bryan says. CBER head Peter Marks says he is not concerned if agency staff later go to work for industry; suggests increased staffing and reorg could help cut down on gene therapy IND clinical holds.
You may also be interested in...
US FDA Opens OTP Director Search Again
The new job notice offers a top salary, but also invites questions about the candidate pool attracted by the original solicitation.
US FDA Open To Cell Therapy ‘Assessment Aid’ That Could Speed Development Of Next-Gen Cancer Drugs
A framework for sponsors and the FDA to discuss ways to extrapolate existing data to support a new cell therapy could cut the time to approval.
US FDA Liver Drug Division Acting Director Is Frank Anania
The former Emory professor is now leading the US FDA Division of Hepatology & Nutrition after its inaugural director, Joseph Toerner, moves back to the infectious disease field as acting deputy in FDA’s vaccines office.